Spero Therapeutics names Timothy Keutzer Chief Operating Officer effective Feb 1, 2023

Spero Therapeutics, Inc.

Timothy Keutzer, previously Chief Development Officer, appointed COO effective February 1, 2023.
Base salary set at $459,000; annual cash bonus target of up to 40% of base salary.
Grant of 4-year vesting RSUs worth $500,000 on effective date.
Severance: 9 months salary without Cause/Good Reason; on change of control, 12 months salary plus equity acceleration.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Timothy Keutzer

Chief Operating Officer

SPRO · Spero Therapeutics, Inc.

Effective: 2023-02-01
Filed: February 1, 2023, 6:59 PM ET

On January 30, 2023, the Board of Directors (the “Board”) of Spero Therapeutics, Inc. (the “Company”) appointed Timothy Keutzer as the Company’s Chief Operating Officer, effective as of February 1, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy Keutzer was appointed as Chief Operating Officer at Spero Therapeutics, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On January 30, 2023, the Board of Directors (the “Board”) of Spero Therapeutics, Inc. (the “Company”) appointed Timothy Keutzer as the Company’s Chief Operating Officer, effective as of February 1, 2023

View on SEC.gov

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-021612

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.